Particle.news
Business ❯ Healthcare ❯ Pharmaceuticals
Clinical Trials Weight Loss Drugs Acquisitions GLP-1 Drugs Cancer Treatment Obesity Treatments Oncology Novo Nordisk FDA Regulations Eli Lilly Neuroplastogenic Therapeutics Springworks Therapeutics Multiple Sclerosis Treatments Market Competition Autoimmune Disease Treatments Novartis Weight Loss Treatment Oral Weight Loss Pill Weight-Loss Drugs Tirzepatide Stelara Biosimilar Drugs Weight Loss Treatments COPD Treatment Obesity Drugs Biologic Medicines Partnerships Weight-loss Drugs Merck AstraZeneca Anti-Cancer Drugs Semaglutide Rare Diseases Sales Performance Sarepta Therapeutics Vertex Pharmaceuticals Dupixent Market Readiness Upadacitinib Rinvoq Regulatory Approval Precision Medicine Innovative Drugs Eli Lilly Products AbbVie Inc. Silevertinib GSK plc Rheumatoid Arthritis Rigel Pharmaceuticals Breyanzi Novo Nordisk A/S Clinical-stage Companies Regulatory Affairs Immuno-Oncology New Drug Application Antibody-Drug Conjugates Market Opportunities Orforglipron Weight Management Vaccines Monoclonal Antibodies Radical Innovation Investment Plans Incremental Innovation Anti-Obesity Drugs Alzheimer's Disease Vyndaqel Family of Drugs Pfizer AbbVie Concussion Treatment Vaccine Rollout Pfizer Inc RELYVRIO
December 15 is the deadline to seek lead-plaintiff status in Peters v. MoonLake challenging claims about SLK’s Nanobody advantages.
